Our Stories
Latest News
Innovation
Caring & Giving
Personal Stories
Health & Wellness
Our Heritage
Our Company
About J&J
Our Credo
Our Leadership Team
Corporate Governance
Diversity & Inclusion
Empowering Women
Innovation at J&J
Office of the Chief Medical Officer
J&J Health and Wellness Solutions
Policies & Statements
Code of Business Conduct
Corporate Reports
Products
Consumer Products
Medical Devices
Pharmaceutical Products
Procurement
Value Pillars
Supplier Diversity
Supplier Standards
Careers
What We Do
How We Hire
Job Spotlight
Employee Benefits
Students
Innovation
Career Stories
Media Center
Investors
Corporate Governance
Quarterly Results
SEC Filings
News Releases
Pharmaceutical Pipeline
2016 Health for Humanity Report
Stock Information
Webcasts & Presentations
Our Societal Impact
Global Community Impact
Global Public Health
Global Environmental Health
Citizenship & Sustainability Reporting
Follow Us
Facebook
Twitter
YouTube
LinkedIn
Explore more Johnson & Johnson sites:
Australia
Argentina
Brazil
Canada
Chile
China
Colombia
Costa Rica
Ecuador
Germany
India
Italy
Japan
Mexico
New Zealand / Pacific
Paraguay
Peru
Philippines
Russia
Switzerland
German
English
French
Italian
Uruguay
United States
Venezuela
Press Release Archive
+
View Filters
All Topics
Caring & Giving
Health & Wellness
Innovation
Our Company
Our Heritage
Our Products
All Dates
Last 30 Days
Last 90 Days
Last Year
Sort by Newest
Sort by Oldest
Products & Operating Company
June 19, 2013
Ibrutinib Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Data Published in The New England Journal of Medicine
A second study in relapsed/refractory mantle cell lymphoma (MCL) also published in the online edition
Products & Operating Company
June 19, 2013
Ibrutinib Data Published in The New England Journal of Medicine Show 68 Percent Overall Response Rate in Patients with Relapsed/Refractory Mantle Cell Lymphoma (MCL)
A second study in relapsed/refractory chronic lymphocytic leukemia (CLL) also published in the online edition
Products & Operating Company
June 18, 2013
Latest Data for Type 2 Diabetes Treatment INVOKANA™ (canagliflozin) to be Presented at American Diabetes Association Annual Meeting
Late-Breaking Phase 3 Results and Health Economics Data are Among 17 Accepted Presentations
Products & Operating Company
June 17, 2013
World Health Organization Issues Interim Guidance on Bedaquiline
Products & Operating Company
June 17, 2013
Johnson & Johnson Announces Definitive Agreement To Acquire Aragon Pharmaceuticals, Inc.
Products & Operating Company
June 17, 2013
Mentor Receives FDA Approval For MENTOR® MEMORYSHAPE™ Breast Implants
Products & Operating Company
June 16, 2013
Updated Results of Two Phase 2 ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
Products & Operating Company
June 13, 2013
New 1-Day ACUVUE® TruEye® Brand Contact Lenses (narafilcon A) Now Available In U.S.
U.S. Upgraded to Global Standard of Popular Daily Disposable Brand
Products & Operating Company
June 13, 2013
Codman Neuro Obtains CE Mark For Enhanced REVIVE SE™ Thrombectomy Device
Self-Expanding Clot Removal Device for Ischemic Stroke Features Newly Enhanced Navigation
Products & Operating Company
June 13, 2013
STELARA® Phase 3 Study Published In The Lancet Reports One Year Efficacy And Safety In Treatment Of Active Psoriatic Arthritis
Data Show Interleukin-12/23 Inhibitor STELARA Improved Joint, Soft Tissue and Skin Components of Psoriatic Arthritis
See More Press Releases